CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published ahead of print on November 5, 2009
Clinical Journal of the American Society of Nephrology
© 2009 American Society of Nephrology
doi: 10.2215/CJN.05350709
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by McIntyre, N. J.
Right arrow Articles by McIntyre, C. W.
PubMed
Right arrow Articles by McIntyre, N. J.
Right arrow Articles by McIntyre, C. W.

Tissue-Advanced Glycation End Product Concentration in Dialysis Patients

Natasha J. McIntyre*, Lindsay J. Chesterton*, Stephen G. John*, Helen J. Jefferies*, James O. Burton*, Maarten W. Taal*, Richard J. Fluck*, and Christopher W. McIntyre*,{dagger}

* Department of Renal Medicine, Royal Derby Hospital, Derby, United Kingdom; {dagger} School of Graduate Entry Medicine and Health, University of Nottingham, Nottingham, United Kingdom

Correspondence: Dr. C. McIntyre, Department of Renal Medicine, Royal Derby Hospital, Uttoxeter Road, Derby DE22 3NE, UK. Phone: 44-1332-789344; Fax: 44-1332-789352; E-mail: chris.mcintyre{at}nottingham.ac.uk

Background and objectives: Tissue-advanced glycation end products (AGE) are a measure of cumulative metabolic stress. Assessment of tissue AGE by skin autofluoresence (AF) correlates well with cardiovascular outcomes in hemodialysis (HD) patients. This study aimed to measure and compare tissue AGE levels in HD and peritoneal dialysis (PD) patients and to evaluate the impact of systemic PD glucose exposure.

Design, setting, participants, & measurements: Tissue AGE were measured in 115 established dialysis patients (62 HD and 53 PD) using a cutaneous AF device (AGE Reader; DiagnOptics). Values were compared with an age-matched non–chronic kidney disease database. Review of all previous PD solution delivery/prescription data determined PD glucose exposure.

Results: PD patients were similar in age to HD patients but had a shorter dialysis vintage. There were no differences in ischemic heart disease or smoking history, statin or angiotensin-converting enzyme inhibitor (ACEi) use, lipids, biochemistry, or prevalence of diabetes. More than 90% of both groups had met current dialysis adequacy targets. Skin AF values in PD and HD patients were similar and strongly correlated with historical PD glucose exposure. Skin AF correlated with age in both groups but with dialysis vintage only in PD patients

Conclusions: Cumulative metabolic stress and transient hyperglycemia results in grossly elevated levels of tissue AGE in dialysis patients. In PD patients, this high level of AGE deposition is associated with historical glucose exposure. This observation provides a previously unappreciated potential link between PD exposure to glucose and systemic cardiovascular disease.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by the American Society of Nephrology.